Vetter Pharma-Fertigung GmbH & Co. has been given the go-ahead as a foreign contract manufacturer for the Japanese pharmaceutical market.
The Germany-based company specialising in the aseptic filling of pre-filled injection systems, Vetter received certification from Japan's Ministry for Health, Labour and Welfare in the categories "drug, sterile product", "drug, packaging, labelling and storage" and "medical device, sterilised medical device".
Vetter already partners with international customers to manufacture pre-filled injection systems for the Japanese market. The approval would now see Japan's pharma and biotech companies being allowed to use Vetter as a contract manufacturer for the local market.
New England Peptide (NEP) has expanded its Massachusetts facility with a large scale production suite in a bid to meet demand for custom peptide and antibody services.
"We are seeing steadily increasing demand from customers for expertise in scaling up production quantities to hundreds of grams . . . this expansion gives us the capability to continue to meet this growing market need," NEP science and new technology senior vice president Sam Massoni said.
The 1,000 sq. ft. facility also reflected the company's planned entry into the worldwide market for clinical and commercial-grade peptides.
Urigen Pharmaceuticals and Hyaluron Contract Manufacturing have established a partnership to develop URG101, Urigen's proprietary fixed dose combination of FDA-approved drugs targeting painful bladder syndrome.
"Urigen's development programme with Hyaluron is a critical step forward for URG101," Urigen chief executive and president William Garner said.
Terms of the contract were not disclosed.
Servac Philippines and Swedish pharma and biotech design company Pharmadule AB have signed a memorandum of agreement to construct a $120m pharmaceutical pilot factory in Alabang, Manila, for the manufacture of anti-rabies vaccine.
The MOA states that in "order to arrive at a fixed price for the supply of the pilot plant, Pharmadule will perform a basic design study under a separate contract for the design, supply, reassemble and start-up of the process plant and certain services associated therewith".
Servac has acquired a majority stake in the first Philippine biopharmaceutical company which ahs an outsourcing manufacturing contract with the Research Institute of Tropical Medicine of the Department of Health of the Philippines for the production of anti-rabies vaccine.
When completed the plant is expected to employ more than 100 people.
Patheon is selling off its Niagara-Burlington commercial manufacturing business to privately owned contract manufacturer Pharmetics for $5.75m, plus working capital.
Under the agreement, Pharmetics will acquire the assets, including equipment, facilities and land, at Patheon's facilities in Fort Erie and Burlington in Ontario.
All 250 commercial manufacturing employees are expected to be retained, with the manufacture of all products currently produced at the two sites to continue.
Collectively, the two sites currently serve 14 clients, and manufacture and package about 60 over-the-counter pharmaceutical products in a range of dosage forms.
The transaction is expected to be completed by January 31, subject to closing conditions.